Article Text

Download PDFPDF

Chronic cutaneous lupus erythematosus and topical clindamycin
  1. Andrew J Newman1,
  2. Andrea Schneider2,
  3. Brooke Blumetti1,
  4. Jason Barr1
  1. 1Dermatology Residency, Affiliated Dermatology, Scottsdale, Arizona, USA
  2. 2College of Osteopathic Medicine, Midwestern University, Glendale, Arizona, USA
  1. Correspondence to Dr Andrew J Newman, anewman{at}affderm.com

Statistics from Altmetric.com

Description 

A 64-year-old Caucasian woman was seen in our office for several years for management of her chronic cutaneous lupus erythematosus (CCLE). Her condition consisted of violaceous papules and plaques with some focal atrophy distributed over the upper arms, face and scalp. Histopathology from two 4 mm punch biopsies performed on separate occasions demonstrated features on H&E stain consistent with CCLE: epidermal atrophy and interface dermatitis with superficial perivascular, deep dermal and periadnexal lymphohistiocytic infiltrates containing some plasma cells. Her rash had frustrated her for over 5 years, worsening with increased sun exposure. Her collagen vascular serologies were negative. She had been managed with potent topical corticosteroids with improvement, however, the patient preferred to reserve this for flares of her condition. Interestingly, the patient had correlated dramatic clearing of her CCLE inadvertently after 3 months of applying topical clindamycin gel 1% twice daily (figures 1 and 2), which was initially prescribed to her for mild comedonal acne. Her improvement maintained and her skin clearance was still appreciated at her follow-up visit over 6 months after having initiated the topical clindamycin. During this course, the patient denied having less sun exposure, and she denied using her previously prescribed topical corticosteroids.

Figure 1

Chronic cutaneous lupus erythematosus of the face prior to treatment of topical clindamycin 1%.

Figure 2

Chronic cutaneous lupus erythematosus of the face after 3 months of topical clindamycin 1%.

An intriguing correlation between the use of topical clindamycin and the improvement of CCLE was observed. A possible contributor to this clearance may have been a change in the patient’s exposure to sunlight. However, the authors of this manuscript feel that changes in the patient’s sun exposure could not independently explain the marked skin clearing. First, the seasonal variation (and total radiant ultraviolet light variation) in the desert climate of the Phoenix Valley of Arizona is relatively low. Second, although the patient noticed the improvement during the fall, her skin clearance continued into the following spring and summer (she denied having any changes to her sun-avoidance behaviour). The authors of this manuscript were initially reluctant to think that a topical antibiotic could treat inflammatory dermatoses like CCLE—especially given this condition’s involvement of the superficial and deeper dermis —yet they entertain that topical clindamycin imparted anti-inflammatory properties which improved this patient’s CCLE. Clindamycin has been used in many skin conditions including acne, and it believed to work both as an antibiotic and anti-inflammatory.1 The next step to explore the utility of topical clindamycin in the treatment of CCLE would be to have this patient take at least a 2-month holiday from the topical clindamycin followed by a reintroduction of the medicine to see if her disease would accordingly relapse then remit.

Learning points

  • Clindamycin has been demonstrated to have anti-inflammatory properties and utility in the treatment of non-infectious skin conditions.

  • A patient with chronic cutaneous lupus erythematosus was observed to have clear skin after 3 months of initiating topical clindamycin.

Acknowledgments

We thank the devoted faculty and staff of Honor Health and Affiliated Dermatology of Scottsdale, Arizona for their support and encouragement.

Reference

View Abstract

Footnotes

  • Contributors AS: contributed text in the document, as well as performed a literature review needed for the background of this case. AJN: provided text to the case report. BB: edited the document. JB: was an invaluable medical consult to maintain the accuracy of the medical content.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.